disease management, dietary care, quality of life and more
May is Celiac Disease Awareness Month, and the Celiac Disease Foundation – along with members of the celiac community – have dedicated the month to raising awareness and funds for critical illness research and prevention efforts. advocacy.
Celiac disease is a chronic autoimmune digestive disease that damages small intestinal villi and interferes with nutrient absorption. It affects 1% of the US population and, if left untreated, can lead to debilitating complications including bowel cancer, diabetes, malnutrition, infertility and even death.
Although much is known about the development of the disease and its effects on the body, questions remain about screening, diagnosis and patient care.
In support of Celiac Disease Awareness Month, Healio has compiled eight recent reports that include updates on dietary care, disease management strategies, patient quality of life and more.
Microbiome status unrelated to current celiac disease activity, severity
According to data published in Clinical and translational gastroenterology.
“Celiac disease (CD) investigations have postulated a role for the gut microbiome in multiple aspects of disease development and progression,” Yael R. Nobel, MD, a fellow in gastroenterology and hepatology at Columbia University Irving Medical Center in New York, and his colleagues wrote. “Certain taxa, including Bifidobacterium and Clostridian species such as Faecalibacterium prausnitzii, have a decrease in abundance in patients with active CD or treated CD compared to controls. ” Read more.
A low-FODMAP diet improves gastrointestinal symptoms in patients with celiac disease
According to one study, a short-term, moderately low-FODMAP diet, in addition to a strict gluten-free diet, significantly reduced gastrointestinal symptoms and improved disease-specific health in celiac patients.
“There are no recommendations or guidelines for patients with [celiac disease (CeD)] in remission with persistent symptoms, but dietary interventions, in addition to a gluten-free diet, may be a treatment option for persistent IBS-like symptoms in CeD,” Frida van Megen, a doctoral researcher in the Department of Clinical Services at Oslo University Hospital Rikshospitalet in Norway, and his colleagues wrote in Clinical gastroenterology and hepatology. Read more.
Group education improves symptom management and quality of life in celiac disease
According to research published in BMC Gastroenterology.
“Complete elimination of gluten from the diet is the only treatment available. [for celiac disease]. Failure to adhere to a gluten-free diet (GFD) results in reduced quality of life and worsening of symptoms. However, strict adherence to this diet can be difficult,” Zahra Akbari Namvar, from the Tabriz University of Medical Sciences, and his colleagues wrote. “Individual education from an expert dietitian is the usual management for these patients. … Group education is another method of nutrition education. This method provides more detailed information and support from other patients who suffer from the same disease and promotes discussion of patient issues. ” Read more.
Entering the “Age of Enlightenment” with a New Generation of Celiac Disease Leaders
I’ve been involved with celiac disease for over 30 years, and for a long time it was what I call an orphan disease, with less than a handful of expatriate scholars taking an interest in it.
The irony is that in the 1960s there was great interest in celiac disease in academic gastroenterology, with GI giants publishing about celiac disease before it spread through the desert. A renaissance of interest was born in the 90s and turned into what I call the “Age of Enlightenment”, where celiac disease is not only considered a major gastrointestinal disease, but also as an excellent example of autoimmune disease. It’s getting a lot more attention as a model disease in which we can manipulate the immune system. Read more.
In silico models could identify celiac disease biomarkers
Using in silico models is an effective method for identifying celiac disease biomarkers, according to a presentation at the annual meeting of the North American Society for Pediatric Gastroenterology, Hepatology & Nutrition.
“We found that metabolic modeling can provide a functional link to RNA-seq data,” Isabelle Aldridge, an undergraduate research assistant at the Gastroenterology Data Science Laboratory at the University of Virginia in Charlottesville, said during the presentation. “We have demonstrated the value of this in silico method to identify disease biomarkers and drug targets that will bring us closer to precision medicine in celiac disease.” Read more.
Caring for patients with celiac disease is “a marathon, not a sprint”
If left untreated, celiac disease can lead to a plethora of complications including malnutrition, weakened bones, infertility and miscarriages, nervous system problems and more.
“It’s a really fascinating disease because it’s one of the few diseases that can be treated by strictly removing a particular type of food from the diet,” Lisa M. Fahey, MD, attending physician and co-director of the Celiac Center at Children’s Hospital of Philadelphia, said. Read more.
VIDEO: Brain fog, very common neurocognitive symptoms in celiac disease
In this exclusive video, Alice Bast and Jessica Edwards George, Ph.D., discuss how brain fog and other neurocognitive symptoms affect patients with celiac disease.
“Brain fog doesn’t get as much attention from researchers as gastrointestinal symptoms,” said Bast, CEO of Beyond Celiac, which collaborated with researchers at Northeastern University to help fund a survey of of 1,400 patients with celiac disease or non-celiac gluten sensitivity. Read more.
ZED1227 prevents increased mucosal damage in celiac disease
According to a study published in The New England Journal of Medicine.
“The only treatment available for celiac disease is lifelong adherence to a strict gluten-free diet, a diet that is difficult to maintain. … Additionally, many patients with celiac disease report having persistent symptoms despite adherence to the gluten-free diet. Thus, there is an unmet medical need for an effective treatment adjunct to a strict gluten-free diet,” Detlef Schuppan, MD, PhD, from Johannes Gutenberg University, and his colleagues wrote. “ZED1227 inhibits transglutaminase 2 with high specificity and prevents the formation of deamidated gluten and, presumably, the initial steps of gluten-induced T-cell activation. Our Phase 1 clinical studies…did not show any adverse drug-related effects or signs of drug toxicity. Read more.